BRKR Bruker Corporation

Bruker BioSciences announces its annual new product booth tour for institutional investors and analysts at Pittcon 2006 in Orlando, Florida. The investor tour will start promptly on Tuesday, March 14 at 10 a.m. Eastern Time at the Company's booth #3155, and will last approximately 45 minutes. To participate, please RSVP to michael.willett@bruker-biosciences.com. Bruker BioSciences expects to introduce a host of innovative systems and solutions for life science and advanced materials research. Novel product introductions will include Bruker AXS' unique QUANTAX(TM) QUAD, an innovative EDS system for X-ray microanalysis on electron microscopes, as well as Bruker Daltonics' novel MALDI Biotyper(TM) system for the identification and classification of microorganisms from protein profiles measured by MALDI-TOF mass spectrometry. Pittcon 2006, the 57th Pittsburgh Conference and Exposition on Analytical Chemistry and Applied Spectroscopy, is being held from March 13-16 in Orlando, Florida in the Orange County Convention Center. Bruker BioSciences will exhibit at booth #3155. ABOUT BRUKER BIOSCIENCES (NASDAQ: BRKR) Bruker BioSciences Corporation, headquartered in Billerica, Massachusetts, is the publicly traded parent company of Bruker AXS Inc. and Bruker Daltonics Inc. Bruker AXS is a leading developer and provider of life science, materials research and industrial X-ray analysis tools. Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry. For more information, please visit www.bruker-biosciences.com CAUTIONARY STATEMENT Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's reorganization strategies, integration risks, failure of conditions, technological approaches, product development, market acceptance, cost and pricing of the Company's products, changes in governmental regulations, capital spending and government funding policies, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our respective annual reports on Form 10-K for the year ended December 31, 2004, our most recent quarterly reports on Form 10-Q, and our current reports on Form 8-K. We disclaim any intent or obligation to update these forward-looking statements.